OOIR: Observatory of International Research

Papers

(The H4-Index of AIDS is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study	128
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis	112
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV	75
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV	74
The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture	68
Impaired antibody response to COVID-19 vaccination in advanced HIV infection	66
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection	63
HIV in Iran: onset, responses, and future directions	53
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes	50
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment	49
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents	40
Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM	39
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV	38
Community-based delivery of HIV treatment in Zambia: costs and outcomes	37
Worldwide relative smoking prevalence among people living with and without HIV	37
Comparison of dementia risk after age 50 between individuals with and without HIV infection	37
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen	37
Is tenofovir disoproxil fumarate associated with weight loss?	35
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection	34
Increasing preexposure prophylaxis use and ‘net prevention coverage’ in behavioural surveillance of Australian gay and bisexual men	33
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV	33
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era	30
Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort	29
Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed	28
HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM	27

High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?